News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 505–540
- Matches
- 9588
- Sources here
- 20
- Companies here
- 30
Search results
Stored financial headlines
Active search
9588 matching headlines
Ticker or company: APEMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Stoke (STOK) Session-Level Review: Closes 0.70% Higher at $32.35 on the Day; Nearby Levels: Price Remains Between $30.73 Support and $33.97 Resistance on the Day - Earnings Beat Stocks
STOK
main company
Sharemaestro market context
Price below Trend Line
52 weeks +59.9% · Next-week setup negative 44.6%
Tapestry (TPR) Quarterly Performance Check: The Available Earnings Metric Delivers a Beat in the Latest Session; Share Response: The Stock Records a 4.04% Increase at the Close - Earnings Season Outlook
TPR
main company
Sharemaestro market context
Trend signal active
52 weeks +31.1% · Next-week setup positive 57.2%
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) recently hit a new 52-week high of $108.52, bringing its market capitalization to approximately $9.46 billion. Analysts generally maintain a "Moderate Buy" rating with an average price target of $111.69, and the company exceeded quarterly EPS expectations. Despite this positive performance, …
SYRE
main company
Sharemaestro market context
Trend signal active
52 weeks +496.3% · Next-week setup positive 57.2%
Tapestry Inc. stock rises Tuesday, outperforms market
Tapestry Inc. (TPR) saw its stock rise by 2.51% on Tuesday, closing at $132.26, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the third consecutive day of gains for the company's stock.
TPR
main company
Sharemaestro market context
Trend signal active
52 weeks +31.1% · Next-week setup positive 57.2%
Spyre Therapeutics stock hits 52-week high at 108.16 USD
Spyre Therapeutics (SYRE) stock reached a 52-week high of $108.16, reflecting a 517% return over the past year and a 219% gain year-to-date, with a market capitalization of $9.5 billion. This surge follows positive phase 2 trial results for its ulcerative colitis drug SPY002 …
SYRE
main company
Sharemaestro market context
Trend signal active
52 weeks +496.3% · Next-week setup positive 57.2%
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares
Tenaya Therapeutics CEO Ali Faraz sold $15,777 worth of company shares to cover tax obligations related to vesting restricted stock units. This transaction involved 22,232 shares at prices between $0.6820 and $0.7253. Despite a 44% decline in TNYA shares over the past year, the …
TNYA
main company
Sharemaestro market context
Trend signal ended
52 weeks -35.6% · Next-week setup negative 43.3%
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics' Phase III EMPEROR study for zorevunersen in Dravet syndrome has exceeded its enrollment target, with 162 patients enrolled against a goal of 150, and remarkably, zero patient discontinuations. CEO Ian Smith highlighted the drug's tolerability and the trial's strong retention, attributing it …
STOK
main company
Sharemaestro market context
Price below Trend Line
52 weeks +59.9% · Next-week setup negative 44.6%
International Paper stock holds around $40 as Q2 2026 loss and outage costs weigh on margins
International Paper (IP) stock is trading around $40 as the company reported a Q2 2026 net loss due to mill outages and low profit margins, despite underlying performance beating estimates. Analysts see potential for a 21% upside, with a consensus target price of $48.75, …
IP
main company
Sharemaestro market context
Price above Trend Line
52 weeks -13.5%
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aardvark Therapeutics, Inc. and its officers, alleging violations of federal securities laws. The lawsuit claims that Aardvark's IPO documents were negligently prepared and contained untrue statements regarding the safety and commercial prospects …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics (NASDAQ: AKTX) announced promising preclinical results for its experimental cancer treatment, AKTX-101, a TROP2-directed ADC designed to address the shortcomings of existing antibody-drug conjugates in urothelial cancer. The therapy showed significant tumor growth inhibition in models where standard treatments like Padcev were …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -79.5% · Next-week setup negative 37.7%
KLRA Archives
This page provides news and articles related to Kailera Therapeutics, Inc. (KLRA), a biotechnology company focused on gene therapies for rare genetic diseases. It includes details about the company's stock performance, market data, and a recent article discussing its record-breaking obesity IPO. Kailera Therapeutics …
KLRA
main company
Sharemaestro market context
Stored weekly price path
18 weeks -31.0%
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Sionna Therapeutics, Inc. (SION) following a significant stock drop. The investigation comes after Sionna announced a primary endpoint miss in its PreciSION CF Phase 2a trial and decided not to advance …
SION
main company
Sharemaestro market context
Trend signal ended
52 weeks -73.5% · Next-week setup positive 65.1%
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
United Therapeutics UTHR announced completing enrollment in the phase III TETON-PPF study evaluating Tyvaso (treprostinil) inhalation solution for the treatment of progressive pulmonary fibrosis (PPF). The global registrational study is designed to assess the safety and efficacy of nebulized Tyvaso in this patient population …
UTHR
main company
Sharemaestro market context
Trend signal ended
52 weeks +60.1% · Next-week setup positive 58.0%
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics (NASDAQ: KLRA), a clinical-stage biotech company, is highlighted as a significant obesity IPO that big pharmaceutical companies might target for acquisition. Despite trading below its IPO high, Kailera holds substantial cash reserves and boasts a promising GLP-1 pipeline, including its lead candidate …
KLRA
main company
Sharemaestro market context
Stored weekly price path
18 weeks -31.0%
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a class action lawsuit. The suit alleges that Capricor Therapeutics made misleading statements about changes to its clinical trial analysis for Deramiocel without FDA agreement, potentially jeopardizing …
CAPR
main company
Sharemaestro market context
Price below Trend Line
52 weeks -6.3%
Corcept (NASDAQ: CORT) director plans open-market sale of 103,606 shares
A director at Corcept Therapeutics Inc. (NASDAQ: CORT), David L. Mahoney, has filed a Form 144 notice indicating a planned open-market sale of 103,606 shares of common stock. The shares, valued at approximately $12.16 million, were acquired through open market purchases between May 2020 …
CORT
main company
Sharemaestro market context
Trend signal active
52 weeks +62.8% · Next-week setup positive 56.8%
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald
Cantor Fitzgerald reiterated an "Overweight" rating on Quince Therapeutics Inc. (NASDAQ:QNCX) with a $70.00 price target, following a discussion with management about their drug LAM-001. The firm expressed increased positivity about LAM-001, which is a once-daily inhaled formulation of rapamycin for pulmonary diseases. Quince …
QNCX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -89.6% · Next-week setup negative 43.4%
Relay Therapeutics stock hits 52-week high at 20.83 USD
Relay Therapeutics stock reached a 52-week high of $20.83, currently trading at $20.87 with a market capitalization of $4.52 billion and a 1-year return of 496%. Despite trading above its Fair Value according to InvestingPro, the surge reflects investor confidence. Several analysts have raised …
RLAY
main company
Sharemaestro market context
Trend signal active
52 weeks +438.2% · Next-week setup positive 59.6%
Shareholders sue Aardvark Therapeutics over alleged false statements inflating stock prices post-IPO.
A class action lawsuit has been filed against Aardvark Therapeutics, alleging the company made false statements about its business and financial health, leading to inflated stock prices from its IPO in February 2025 through May 2026. Investors who suffered losses when the truth emerged …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright
HC Wainwright has reissued a "Neutral" rating for Summit Therapeutics (NASDAQ:SMMT), aligning with the analyst consensus of "Hold" and an average target price of $24.25. The company's shares are trading near their 52-week low at $12.63, and it reported a quarterly EPS of ($0.28), …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX
The article provides a title for Viking Therapeutics, Inc. Revenue Breakdown (NASDAQ:VKTX) and indicates that it is a financial page on TradingView. However, the content primarily consists of navigation links, disclaimers, and website feature lists rather than actual revenue breakdown data. It mentions market …
VKTX
main company
Sharemaestro market context
Trend signal active
52 weeks +27.7%